In summary, our findings demonstrate a potent antitumor role of AIM2 inflammasome activation and reveal the feasibility of combined strategies for AIM2 inflammasome activation and intravesical BCG perfusion therapy for BLCA treatment. This evidence concerns the gene AIM2 and bladder transitional cell carcinoma.